fda bpc-157 approval status RFK Jr pushes for of peptide | Eric Topol, MD posted on the topic FDA's Overreach on Compounded Peptides

Cagrilintides mechanism provides additive or synergistic potential when studied alongside incretin-based therapies

doi: 10.1371/journal.pone.0132421 36 SteinE

Aggressive mixing can damage the molecular structure and reduce potency

\n\n\n\n BPC-157 Organ Protection Research: Liver, Kidney, and Beyond \n\n\n\n Beyond the organ systems already discussed, preclinical research has explored BPC-157s potential protective effects across a broad range of additional tissue types including the liver, kidneys, cornea, and periodontal tissue a scope that underscores the compounds apparent systemic rather than tissue-specific mode of action